Ƶ

Osteoporosis Drug Wins; Tramadol and Blood Sugar

— News and commentary from the endocrinology world

Ƶ MedicalToday
ENDOBREAK centered between 8 illustrated body organs.

This article is a collaboration between Ƶ and:

High-dose combination for osteoporosis was better than standard treatment for improving biomarkers of bone health in a post-marketing study. (Lancet Diabetes & Endocrinology)

And a similar finding emerged from a study of -- alendronate (Fosamax) or risedronate (Actonel) -- plus etidronate (Didronel). (Journal of Bone and Mineral Research)

The FDA granted fast track designation to for the prevention of renal failure and chronic kidney disease in people with type 2 diabetes, AstraZeneca announced.

Analysis of adverse event reports . "The takeaway message is to warn physicians about the likelihood of low blood sugar (and/or high insulin content), in particular if the patient is predisposed to diabetes," said study author Ruben Abagyan, PhD, of the University of California San Diego, in a statement. (Scientific Reports)

The combination succeeded in a phase II trial in people with hypercholesterolemia and type 2 diabetes, with mean LDL reduction of 40%, drugmaker Esperion announced.

High blood sugar may explain why people with diabetes are at a higher risk for some cancers. (ScienceDaily)

For menopausal women, waist size is more reliable at rather than BMI. "Not all fat is the same, and central obesity is particularly dangerous because it is associated with risk for heart disease, the number one killer of women," said Stephanie Faubion, medical director of the North American Menopause Society. (Menopause)

In related news, type 2 diabetes may add to for women going through menopause. (Reuters)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.